Business Context and Reporting Period
This Form 8-K Current Report was filed by Exagen Inc. on September 21, 2020. The filing discloses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director effective October 1, 2020.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its authorized size from eight to nine members.
- New Appointment: Wendy Johnson was appointed as a Class III director, with a term expiring at the 2022 annual meeting.
- Committee Assignment: Ms. Johnson was appointed to the Audit Committee, which will now consist of Jeff Elliott, Wendy Johnson, and Tina S. Nova, Ph.D.
Guidance, Outlook, and Compensation
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding compensatory arrangements for the new director:
- Equity Grant: Ms. Johnson will receive an option to purchase 15,000 shares of common stock at fair market value, vesting over three years in equal monthly installments.
- Cash Compensation: She will receive cash compensation in accordance with the Company's non-employee director program.
- Indemnification: Ms. Johnson will enter into the Company's standard indemnification agreement for directors.
Key Facts for Investor Verification
- Verify the effective date of the Board expansion and Ms. Johnson's appointment (October 1, 2020).
- Confirm the vesting schedule of the 15,000 share option grant.
- Review the composition of the Audit Committee post-appointment.
- Note that Ms. Johnson is considered an independent director under Nasdaq Global Market listing requirements.